The international regulation of psychedelic drugs is primarily governed by the United Nations Convention on Psychotropic Substances of 1971. Under this treaty, psychedelic substances are classified into schedules based on factors such as their recognised medical use, potential for abuse, and associated public health risks.
Individual countries implement these international obligations through their own national laws and regulatory frameworks, which determine how psychedelic substances may be researched, manufactured, imported, exported, prescribed, or used in clinical settings. As a result, regulations can vary significantly between jurisdictions, with some countries permitting controlled medical research and therapeutic use, while others maintain stricter restrictions.
As scientific understanding of psychedelic compounds continues to evolve, regulators around the world are increasingly reviewing existing policies to support approved clinical research and the development of new therapeutic applications within carefully controlled regulatory environments.
